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Summary Inactivation of the tumour-suppressor gene p53 has been described as one of the most common molecular changes found in lung
tumours. Our purpose was to study the prognostic value of p53 alterations and to determine whether some specific mutation type in the p53
gene could be associated with poor clinical evolution in non-small-cell lung cancer (NSCLC) patients. To this end, we studied 81 resected
primary NSCLCs in order to detect p53 alterations. p53 protein accumulation was analysed using immunohistochemistry methods; p53 gene
mutations in exons 5-9 were studied using polymerase chain reaction-single-strand conformation polymorphism and sequencing techniques.
p53 protein was immunodetected in 46.9% of lung carcinomas and 44.7% of p53-immunopositive tumours showed p53 mutations. Survival
analysis was performed on 62 patients. No survival differences were found for patients with orwithout p53 immunopositivity. A shorter survival
was found in patients with underlying p53gene mutations, mainly in patients with squamous cell lung tumours; the worst prognosis was found
when mutations were located in exon 5 (P= 0.007). In conclusion, the location of p53 mutations might be considered as a prognostic indicator
for the evaluation of poor clinical evolution in NSCLC patients.
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Lung carcinomas constitute one of the leading causes of cancer
mortality in the world and is the leading cause in the United States.
Lung tumours are classified on the basis of histological type. The
two main types are small-cell lung cancer (SCLC) and non-small-
cell lung cancer (NSCLC). Non-small-cell lung cancer constitutes
the majority group and consists of adenocarcinomas, squamous
cell carcinomas, large-cell carcinomas and other rare types (Travis
et al, 1995).
Inactivation of tumour-suppressor gene p53 has been shown to
be involved in the development of non-small-cell lung cancer
(Passlick et al, 1994). The p53 gene encodes a nuclear phospho-
protein that is a potent transcriptional activator with a DNA-
binding domain in its C-terminal region (Kern et al, 1991; Ullrich
et al, 1992). Several reports demonstrate that the p53 protein has
an important role in the negative regulation of the cell cycle,
arresting cells in G, phase in response to DNA damage (Kuerbitz
et al, 1992; Smith et al, 1995). The elevation ofp53 protein levels
in response to DNA damage leads to activation ofthe transcription
of certain genes regulated by p53, such as an inhibitor of cyclin-
dependent kinase activity (p21/CIP/WAF) (El-Deiry et al, 1993;
Dulic et al, 1994). Additionally, p53 is involved in apoptosis
mechanisms (Claire and Fisher, 1995; Guillouf et al, 1995).
Missense mutations in exons 5-8 are the most frequent abnor-
mality detected in thep53 gene. These mutations lead to stabiliza-
tion ofthe protein in the nucleus. While the wild-type p53 protein
has a half-life of less than 30 min, the mutated p53 protein has a
half-life of several hours (Finlay, 1992). For this reason, routine
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immunohistochemistry methods have been used to detect the
abnormal protein and, usually, protein accumulation data have
been correlated with p53 gene mutations. However, recent data
suggest that the presence of the p53 protein stabilized in the
nucleus does not always guarantee an underlying mutation of the
gene (Bourdon et al, 1995; Top et al, 1995).
Regarding the prognostic role of p53, in almost all studies
testing human NSCLC, p53 abnormalities in the gene have been
associated with a poor survival rate (Horio et al, 1993; Mitsudomi
et al, 1993). However, other authors have found a better outlook in
patients with p53-mutated tumours (Top et al, 1995). Whereas
some studies have reported a favourable prognosis linked to p53
protein stabilization in the nucleus (Lee et al, 1995), others have
found a clinical correlation with poor prognosis (Quinlan et al,
1992; Carbone, 1994) or no association (Passlick et al, 1995).
In order to clarify these conflicting studies, we investigated 81
tumours from patients affected by non-small-cell lung cancer and
subjected to radical surgery to detect p53 abnormalities. The
objectives of our work were, firstly, to establish whether these
genetic alterations have any relationship to clinicopathological
features or shortened survival and, secondly, to determine whether
some specific type ofmutation in thep53 gene could be associated
with a poor clinical evolution in NSCLC patients.
MATERIALS AND METHODS
Patients and tumour samples
The study population consisted of 81 patients (79 men and two
women), with a median age of 62.2 ± 9.25 years, who had under-
gone surgery for lung carcinoma between 1990 and 1994 at San
Carlos Hospital in Madrid. Preoperative evaluation included: chest
radiography, fibreoptic bronchoscopy and biopsy, when possible;
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Table 1 Oligonucleotide sequences used for p53gene amplification and sequencing, and length of amplified fragments
Length
Exon Amplification (bp) Sequencing
p53(5) s 5'-TTTCAACTCTGTCTCCTTCCT-3' 229 s 5'-CCTTCCTCTTCCTGGAGTAC-3'
a 5'-GCCCCAGCTGCTCACCATC-3' a 5'-AGCTGCTCACCATCGCTATC-3'
p53(6) s 5'-CACTGATTGCTCTTAGGTCTG-3' 144 s 5'-TCTTAGGTCTGGCCCCTCCT-3'
a 5'-AGTTGCAAACCAGACCTCAG-3' a 5'-ACCAGACCTCAGGCGGCTCA-3'
p53 (7) s 5'-GTGTTGTCTCCTAGGTTGGC-3' 150 s 5'-CCTAGGTTGGCTCTGACTGT-3'
a 5'-TGTGCAGGGTGGCAAGTGGC-3' a 5'-GGGTGGCAAGTGGCTCCTGA-3'
p53 (8) s 5'-CCTATCCTGAGTAGTGGTAA-3' 165 s 5'-TGGTAATCTACTGGGAGCGA-3'
a 5'-TCCTGCTTGCTTACCTCGCTT-3' a 5'-TGCTTACCTCGCTTAGTGCT-3'
p53(9) s 5'-TTGCCTCTTTCCTAGCACTG-3' 118 s 5'-CTTTCCTAGCACTGCCCAAC-3'
a 5'-ACTTGATAAGAGGTCCCAAG-3' a 5'-CCCAAGACTTAGTACCTGM-3'
s, Sense primer; a, antisense primer.
Table 2 Histological characteristics and frequency of p53 abnormalities in lung tumours
p53 Immunopositivity p53mutation
Characteristic No. of cases No. (%) Pvalue No. (%) P-value
Tumour stage
1 37 17 (45.9) 0.259 7 (18.9) 0.411
11 5 3 (60) 1 (20)
IIIA 30 16 (53.3) 9 (30)
IIIB 4 2 (50) 0 (0)
IV 5 0 (0) 0 (0)
Histology
SCC 52 25 (48.1) 0.961 12 (23) 0.499
AC 20 9 (45) 3 (15)
LCUC 9 4 (44.4) 2 (22.2)
Differentiation
Well 12 2 (16.6) 0.041 1 (8.3) 0.407
Moderately 35 16 (45.7) 7 (20)
Poorly 34 20 (58.8) 9 (26.5)
Total 81 38 (46.9) 17 (21)
fine-needle aspiration, when the tumour was not seen at broncho-
scopy; chest and upper abdominal computerized tomography (CT)
to evaluate lungs, mediastinum, liver and adrenals; cranial CT,
when neurological symptoms were present; and measurement of
forced expiratory volume in 1 s (FEVy) and vital capacity (VC)
and the use of serum tumour markers (SCC, CEA and CEA 125).
During the first 3 years' follow-up, we performed clinical exami-
nation, chest radiography and used serum tumour markers every
3 months; bronchoscopy and thorax and upperabdominal CT were
performed twice a year. During the next 2 years, visits and explo-
rations were reduced to half.
Tumours were pathologically staged using the tumour node
metastasis (TNM) system (Mountain, 1986). Thirty-seven patients
(46%) had stage I tumours; five (6%) had stage II; 30 (37%) had
stage IIIA; four (5%) had stage HIB; and five (6%) had stage IV
tumours. Patients who had stages I, II and IIIA tumours were
subjected to curative surgery, whereas only a biopsy was taken
from patients who suffered from more extensive disease (tumours
in stage IIIB and IV).
All genetic alterations were detected in tumour samples
containing more than 80% tumour cells. To confirm this, cryostat-
sectioned haematoxylin-eosin-stained samples from each tumour
block were examined microscopically by two independent pathol-
ogists. In all cases, non-tumour tissues were used as a control.
Non-tumour samples were selected from macroscopically normal
areas ofsurgical specimens.
All tumours weretypedaccording to WorldHealth Organization
(WHO) criteria (Sobin, 1982): 52 tumours (64%) were squamous
cell carcinomas (SCC); 20(25%) were adenocarcinomas (AC) and
nine (11%) were large-cell undifferentiated carcinomas (LCUC).
Twelve tumours (15%) were well differentiated, 35 (43%) moder-
ately and 34 (42%) poorly differentiated.
Immunohistochemical detection of p53 protein
accumulation
Accumulation of the p53 protein in the tumour cell nuclei was
detected using immunohistochemistry techniques. Thus, 6-jm
frozen sections were cut from each tumour and from non-tumour
tissues on a cryostat. Sections were air dried and fixed in acetone
at 4°C for 10 min. Immunohistochemical staining was carried out
using the avidin-biotin-peroxidase complex (ABC) technique
(Vectastain ABC Kit; VectorLaboratories, Burlingame, CA, USA)
(Hsu et al, 1981) and polyclonal antibody (PAb) 1801 (Oncogene
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tumour cells had stained nuclei. Seven positive cases had 10% of
the tumourcell nuclei staining forp53 antigen. Therefore, samples
scored as positive for p53 expression exhibited intense nuclear
staining in more than 10% of the tumour epithelium but not in
adjacent normal epithelial or stromal tissue.
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Figure 1 Detection of p53 gene mutations by SSCP and sequencing
analysis. A, B and C show point mutations detected in exons 5, 8 and 7
respectively. (A) SSCP analysis and (B) sequencing analysis characterizing
the p53 mutation detected by SSCR Lanes N, corresponding to normal
tissue, show two expected single-strand DNA bands. Lanes T, corresponding
to tumour tissue, show single-strand DNA bands with a mobility shift
Science, Uniondale, NY, USA) as the primary antibody. This anti-
human p53 monoclonal antibody specifically recognizes an N-
terminal epitope between amino acids 32 and 79 in the mutant and
wild-type protein (Banks et al, 1986). As a positive control, a
section of a lung carcinoma with high p53 expression was included
in all the assays performed, and the corresponding normal tissue
was used as a negative control.
Sections of tumours were examined for evidence of nuclear
staining with a semiquantitative assessment ofsignal intensity and
proportion of cells staining. In 14 cases, the density of positive
p53 gene mutations analysis
To assess whether immunopositivity for p53 protein correlates
with the presence ofstructural alterations in the gene, we identified
p53 mutations in exons 5-9 using more labour-intensive methods,
such as single-strand conformation polymorphism (SSCP) and
sequencing. We analysed frozen surgical tumour specimens and
their corresponding normal tissue from all 81 patients studied.
DNA isolation from fresh tumour and non-tumour tissue was
performed using the DNA extraction protocol described by Blin
and Stafford (1976).
Polymerase chain reaction-single-strand conformation
polymorphism analysis (PCR-SSCP)
Analysis of single-strand conformation polymorphism (SSCP)
was performed as described by Orita et al (1989). DNA samples
were amplified for SSCP analysis from exons 5, 6, 7, 8 and 9 ofthe
p53 gene. Each amplification reaction was carried out in a 10-,ul
reaction volume containing: 0.1 tg ofgenomic DNA, 1 gM ofeach
primer, 0.2 mm ofeach deoxynucleoside triphosphate, 10 mM Tris
HCI (pH 8.3), 50 mm potassium chloride, 2 mm magnesium
chloride, 0.5 U ofTaq DNA Polymerase (Perkin Elmer, Roche, NJ,
USA) and 0.5 gl [cX-32P]dCTP (3000 Ci mmol-') (Nuclear Iberica,
Spain). Reaction mixtures were subjected to 30 cycles ofthe PCR
at 94°C, 55°C and 72°C for 0.5, 0.5 and 1 min, respectively, in a
Perkin Elmer thermocycler (Gene Amp PCR System 2400). The
primers used and the length offragments are shown in Table 1. An
aliquot of the PCR-SSCP reaction mixture (1 ,ul) was diluted in
100 ,ul of 0.1% sodium dodecyl sulphate (SDS), 10 mM EDTA.
Then, 10gl of this solution was mixed with 10 p1 of 95%
formamide, 20 mm EDTA, 0.05% bromophenol blue and 0.05%
xylene cyanol, heated at 95°C and applied (1 ,ul per lane) to a 6%
polyacrylamide gel containing 90 mM Tris borate (pH 8.3), 2 mM
EDTA and 10% glycerol. Electrophoresis was performed at 30 W
for 4-6 h under continuous cooling. Finally, the gel was dried and
exposed to radiographic film at room temperature for 12-24 h. The
above protocol yielded the highest sensitivity for p53 mutations
compared with several variations of this procedure, including
changes in the gel glycerol content and in the temperature of
electrophoresis. In our hands, SSCP can detect mutations in the
presence of 90% contaminating normal tissue. Moreover, the
sensitivity ofthe SSCP method was checked by known mutations
selected from a colorectal tumour population previously analysed
in our laboratory.
Direct DNA sequencing
In order to characterize p53 gene mutations, we sequenced all
DNA fragments showing an abnormal mobility shift as detected by
SSCP analysis. Additionally, to avoid the false-negative cases
detected by some authors with the SSCP technique, we sequenced
all the samples showing p53 immunopositivity to compare the
SSCP data with direct sequencing. In our study, we did not find
any SSCP false negatives, and allp53 mutations were detected in
the group of tumours with p53 immunopositivity. Nucleotide
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Table 3 Description of p53gene mutations found in non-small-cell lung tumours
Tumor No. Stage Histology Differentiation Exon Codon Mutation Amino acid change
102 T IIIA SCC Poorly 5 170 ACG-*ACA Thr-Thr
122 T IIIA LCUC Poorly 5 159 GCC-*ACC Ala-*Thr
251 T AC Moderately 7 236 TAC-TGC Tyr-*Cys
277 T SCC Moderately 7 248 CGG-*CTG Arg-*Leu
295 T SCC Moderately 5 163 TAC-4TGC Tyr-*Cys
299 T LCUC Poorly 7 242 TGC->TTC Cys-*Phe
249 T IIIA AC Poorly 7 249 AGG-*AGC Arg-*Ser
339 T AC Moderately 7 237 ATG->GTG Met-Val
343 T IIIA SCC Poorly 5 158 CGC-*CTC Arg-*Leu
351 T II SCC Moderately 5 164 AAG-4CAG Lys->Gln
361 T SCC Poorly 8 288 AAT--AGT Asn-*Ser
3737 SCC Poorly 5 163 TAC--CAC Tyr--His
375 T IIIA SCC Well 5 163 TAC-*CAC Tyr-4His
404 T IIIA SCC Poorly 5 179 CAT-*CGT His->Arg
408 T IIIA SCC Moderately 5 174 AGG-)AAG Arg-4Lys
410 T IIIA SCC Poorly 8 296 CAC-*CTC His-4Leu
420 T IIIA SCC Moderately 5 157 GTC-)GTT Val--Val
Table 4 Distribution of p53 mutations by exon and histology
Histology Exon
Exon 5 Exon 7 Exon 8
SCC 9 1 2
AD 0 3 0
LCUC 1 1 0
sequences for exons 5-9 ofp53 were determined by the dideoxy
termination method (Sanger et al, 1977), using the PCR Template
Preparation Kit for ss DNA sequencing and the T7 DNA
Polymerase Kit (Pharmacia, Biotech, Uppsala, Sweden) with
[aX-35S]dATP (1000 Ci mmol-') (Nuclear Iberica, Spain), following
the supplier's conditions. All mutations were confirmed by
sequencing three independent PCR products to ensure that the
results were not due to sample cross-contamination or the genera-
tion of PCR artefacts from multiple rounds of PCR. The samples
were run on 6% polyacrylamide/7 M urea gel at 45 W for 3 h. The
primers used forp53 sequencing are shown in Table 1.
Clinical correlations and survival analysis
The stage, histology and differentiation grade of lung tumours
included in this work were related to the presence of the p53
abnormalities considered. The results were evaluated by the chi-
square test, and a P-value < 0.05 wasjudged to be significant.
To construct the survival curves, following the Kaplan and
Meier method, we only considered patients who had stage I, II and
IIIA tumours. We have also excluded the patients who died in the
post-operative period. Thus, the number ofpatients included in the
survival study was 62. The log-rank test was used to compare the
survival curves statistically. Results were considered to be signifi-
cant for P-values < 0.05. The Cox proportional hazards model was
used to identify which independent factorsjointly had a significant
influence on survival.
RESULTS
Relationship between p53 protein immunopositivity
and p53gene mutations
p53 protein was immunodetected in 46.9% ofthe lung carcinomas
analysed. No significant correlation was found between p53
immunostaining and tumour stage or histological type. However, a
significant correlation was seen between p53 protein stabilization
and tumour differentiation grade (P = 0.041). Our data indicate
that p53 immunopositivity was significantly prevalent in poorly
differentiated tumours (58.8%) (Table 2).
p53 gene mutations, detected by the PCR-SSCP technique and
direct sequencing (Figure 1), were always found in lung tumours
that were positive for p53 protein staining in the nucleus.
However, only 44.7% of p53-immunopositive tumours showed
underlying p53 gene mutations in exons 5-9.
A non-significant correlation was found between p53 gene
mutation and tumour stage, histology or differentiation grade. For
the differentiation grade, we found a trend toward accumulation
of p53 gene mutations in moderately or poorly differentiated
tumours, but the differences were not found to be significant
(Table 2).
All positive tumours forp53 gene mutations showed heterozy-
gosity as, in all cases, only one of the alleles was altered. Among
these mutations, 58.8% were located in exon 5 (20% transversions
and 80% transitions); 29.4% in exon 7 (60% transversions and
40% transitions) and 11.8% in exon 8 (50% transversions and 50%
transitions) (Table 3). Therefore, of all the mutations detected,
64.7% were transition type. All 17 patients bearing p53 gene
mutation showed single-point mutations. Among those, 15 were
missense mutations (88.2%) and two were silent mutations
(11.8%) (Table 3). Although the presence ofp53 mutations did not
show a significant preference for any histological subtype (12 of
52 or 23% in squamous cell carcinomas compared with 5 of 29 or
17.2% in the non-squamous histologies analysed), we found an
association between the squamous cell histology and the presence
ofp53 mutations located in exon 5. In fact, of the ten p53 exon 5
mutations, nine were detected in lung tumours pertaining to
squamous cell histology (Table 4).
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Figure 3 (A) Survival curves for radically resected NSCLC patients in relation to p53 gene mutations. In the Kaplan-Meier survival analysis, 8 of the 16 patients
with p53 gene mutations died during the follow-up period (median 135 weeks) compared with 10 of the 46 with no mutation in the p53 gene (p53 mutated/p53
non-mutated, P = 0.04 by log-rank test). Mutations were located in exon 5 in seven of the eight patients with p53 gene mutation positive tumours who died
during the follow-up period (p53 exon-5 mutated/p53 non-mutated, P = 0.007 by log-rank test). (B) Kaplan-Meier survival curves for radically resected SCC
patients in relation to p53 gene mutations. Eight of the 28 SCC patients with no mutation in the p53 gene died during the follow-up period (median 135 weeks)
compared with 8 of the 12 patients with p53 gene mutation (p53 mutated/p53 non-mutated, P = 0.006 by log-rank test). Mutations were located in exon 5 in
seven of the eight patients with p53 gene mutations who died during the follow-up period
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Table 5 Independent prognostic factors in NSCLC patients by Cox regression analysis
Factor Risk ratio 95% C P
Stage
11 vs 8.22 1.73-39.05 0.008
IIIA vs 11 6.22 1.99-19.37 0.001
p53 Mutation
Mutated vs non-mutated (considering all histological types) 1.85 0.65-5.21 0.243
Mutated vs non-mutated (only considering the SCC group) 4.73 1.20-18.57 0.026
Exon 5 mutated vs non-mutated (considering all histological types) 2.76 0.84-9.01 0.061
Cl, confidence interval
Table 6 Summary of p53 accumulation and p53 mutations in non-small-cell lung cancer series
Reference No. of p53 IHCa p53 mutb Correlation between Effect of p53 IHCa Effect of p53 mutb
patients (%) (%) p53 IHCa and p53 mutb(%) on survival on survival
Mitsudomi et al (1993) 120 ND 43 ND ND Negative
Horio et al (1993) 71 ND 49 ND ND Negative
Carbone et al (1994) 85 64 51 67 Negative No association
Ryberg et al (1994) 108 ND 32 ND ND ND
Fong et al (1995) 108 ND 25 ND No association ND
Fujino et al (1995) 35 34 26 75 ND ND
Top et al (1995) 54 52 50 68 Favourable prognosis
(considering p53alterations on a whole)
Shipman et al (1996) 24 71 38 53 ND ND
ap53 protein accumulation positive cases. bp53 mutation positive cases in exons 5-8. ND, no data.
DISCUSSION
Changes in p53 are among the most common molecular events
found in all types oflung tumours, suggesting a crucial role forpS3
in bronchial carcinogenesis. However, the prognostic significance
ofp53 abnormalities in lung cancer is still poorly understood.
We have detected p53 immunostaining in 46.9% of lung
tumours analysed, which corresponds to the findings previously
reported in the literature (Passlick et al, 1995) using the same anti-
body PAb 1801. Other authors have published higher percentages
using different antibodies (Lee et al, 1995). According to our
results, only 44.7% of p53-immunopositive tumours have under-
lying gene mutations in exons 5-9. In Table 6, we summarize
different studies evaluating p53 molecular abnormalities and/or
p53 protein accumulation in NSCLC patients. In this table, we
show the lack of concordance, reported by different authors,
between p53 protein nuclear accumulation and p53 gene muta-
tions. Carbone et al (1994) found a concordance of67%, Fujino et
al (1995) 75%, Top et al (1995) 68%, and Shipman et al (1996)
reported that the concordance between p53 protein accumulation
and p53 gene mutation data was only of 53%. Therefore, it seems
clear that investigation for p53 abnormalities requires molecular
studies, and immunostaining positivity should not be taken as
equivalent to molecular abnormality in the gene.
The lack of correlation between p53 immunostaining and p53
mutation data found in this work could in fact be accounted for by
the presence of missense mutations outside exons 5-9 leading to
protein accumulation. Some studies of mutations outside this
region, in different types of tumours, suggest that 10-25% of all
mutations occur outside exons 5-8, but in these regions there is a
predominant pattern of null mutations (Hartmann et al, 1995) that
do not result in protein accumulation. Another explanation for the
lack of concordance between p53 accumulation and gene muta-
tions could be the concurrent stabilization of p53 protein as it is
bound and inactivated by endogenous proteins, such as mdm-2
(Momand et al, 1992) orby exogenous DNA tumour virus proteins
(Scheffner et al, 1990). Other mechanisms could be proposed
considering the important role played by p53 in the regulation of
the cell cycle (Kuerbitz et al, 1992; Guillouf et al, 1995; Smith et
al, 1995). In this regard, p53 protein could be overexpressed to
activate certain genes regulated by p53, such as p21/CIP/WAF
(El-Deiry et al, 1993; Dulic et al, 1994), whose protein product
binds and inactivates CDK4, arresting cells at the G1/S transition
of the cell cycle and allowing p53 to repair the DNA damage. In
addition, p53 protein is also inducedduring cell deathby apoptosis
(Claire and Fisher, 1995; Guillouf et al, 1995). Wild-type p53
protein overexpression and accumulation in the cellular nucleus
may activate apoptosis as a protection mechanism throughout
tumorigenesis.
We have found a rate of 21% for p53 gene mutation. Data
reported in the literature for resected NSCLC vary greatly (Table
6). Thus, in the most recentmolecular studies onp53, we find inci-
dences for p53 gene mutations in NSCLC varying from 51%
(Carbone et al, 1994) to 25% (Fong et al, 1995).
We also report a lack ofcorrelation between p53 protein or gene
alterations and clinicopathological tumour characteristics, such as
tumour stage and histology. In other lung tumour series, p53
mutations have been associated with tumours of squamous cell
histology (Mitsumomi et al, 1993). However, a significant associ-
ation was found between p53 protein accumulation and differenti-
ation grade, p53 overexpression or mutation being prevalent in
poorly differentiated lung tumours. These results could indicate
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the participation of p53 alterations in the cell dedifferentiation
process.
In our tumour population, we have identified 17p53 mutations.
Eleven of these (64.7%) represented transition mutations, a
frequency which differs from that reported by other authors in
NSCLC (Chiba et al, 1990). However, in other tumoursp53 muta-
tions commonly involve G to A transitions and, in general, the
type of mutation reflects the mutagen involved as specific
mutational spectra are associated with individual mutagens. For
example, in some situations, benzo[a]pyrene can cause G to T
transversions (Chiba et al, 1990), while alkylator exposure
resulting in the production of 06-methylguanine causes predomi-
nantly G to A transitions (Loechler et al, 1984). Thus, the pattern
of p53 mutations in different series of lung tumour carcinomas
may be attributed to exposure to different mutagens.
While the importance ofp53 mutations in the pathogenesis of
human lung cancer is well established, it is not clear whether the
presence or absence of p53 mutations or overexpression of p53
protein adversely affects an individual patient's chances for
survival. In fact, there is significant controversy over the prog-
nostic importance of abnormalities in the p53 gene in resected
NSCLC, and only a few authors have evaluated both molecular
abnormalities and protein overexpression in a cohort of patients
with adequate staging and follow-up (Table 6). Regarding the
effect of p53 protein stabilization on the clinical evolution of
patients, our data indicated that p53 immunopositivity was not
associated with a poor prognosis in non-small-cell lung carci-
nomas. However, contradictory studies have been published
regarding p53 immunopositivity as a prognostic indicator in
NSCLC. Some investigators have associated nuclear staining with
a favourable prognostic influence in lung cancer (Lee et al, 1995;
Passlick et al, 1994). Recently, Passlick et al (1995) reported that
p53 protein overexpression is not associated with an unfavourable
prognosis in patients with early-stage NSCLC. Passlick et al
(1995) considered that wild-type p53 protein overexpression
might reflect a specific cellular response to certain carcinogens.
Thus, lung tumour cells with high amounts ofwild-type p53 might
be able to protect themselves more effectively against exogenous
DNA-damaging agents. Other authors investigating p53 protein,
however, have reported that p53 immunopositivity is a negative
prognostic factor in NSCLC (Quinlan et al, 1992; Carbone, 1994).
Finally, no differences in prognosis have been found by others
(Brambilla et al, 1993).
Regarding p53 mutations and the clinical evolution of lung
cancer patients, our results indicate that p53 gene mutations
predict a shorter survival in NSCLC patients. The group of squa-
mous cell carcinoma patients with this alteration showed the worst
prognosis. The presence ofp53 mutations in this group ofpatients
was an independently significant parameter as established from the
multivariate statistical analysis. A few studies can be found in the
literature examiningp53 gene alterations in relationship to clinical
evolution of NSCLC patients. These studies describe, in general,
p53 gene mutations as a significant indicator of poor prognosis
(Horio et al, 1993; Mitsudomi et al, 1993). Moreover, we found a
significant poor clinical evolution whenp53 mutation was located
at exon 5, a borderline independent significant parameter, the
group of squamous cell carcinoma patients with this alteration
showing the worst prognosis. In spite of p53 exon 5 mutations
being associated with a significant increase in the risk of death
from breast cancer (Seshadri et al, 1996) and with lympho
proliferative disorders (Gandini et al, 1996), this is the first study
analysing NSCLC series in which a correlation has been estab-
lished between the location of the p53 gene mutation and the
clinical evolution ofpatients. p53 exon 5 encodes for amino acids
126-186 in the protein, which is part of the central 'core' domain
(residues 102-292) that is essential for sequence-specific DNA
binding. Missense point mutations within this domain abolishp53-
suppressor function and are linked with the development of over
half of all human cancers. There is evidence that mutations in the
central core domain appear to cause p53 to adopt an alternative
'mutant' conformation. Some mutants can be induced to fold back
into the wild-type form, recovering specific DNA binding function
(Milner, 1995).
In conclusion, our results indicate that p53 exon 5 mutations
correlate with a poorer survival in patients affected by NSCLC,
mainly in patients with squamous cell lung tumours. Moreover,
our data also indicate the need for further molecular studies to
investigate p53 abnormalities, as p53 protein immunopositivity
does not always guarantee the presence of gene alterations.
Characterization of p53 mutation type could be used as a prog-
nostic indicator of poor clinical evolution in NSCLC patients to
evaluate the benefit of adjuvant therapy in patient populations
submitted to radical surgery.
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